


# THE POWER OF PLUS WITH PURAPLY® AM

Native extracellular matrix scaffold + sustained antimicrobial effectiveness within the product to support wound healing and aid in granulation tissue formation<sup>1-4</sup>




## NATIVE, CROSS-LINKED ECM

- Provides a scaffold for cellular migration and proliferation<sup>5</sup>
- Resists protease degradation<sup>3,6,7</sup>
- Inhibits a wide range of MMPs and controls excess proteases<sup>3,6,7</sup>



## BROAD-SPECTRUM PHMB

- Proactively disrupts bioburden<sup>1,3,8</sup>
- Exhibits no known bacterial resistance to date<sup>3,8,9</sup>
- Demonstrates high tissue compatibility and low cytotoxicity<sup>2,8,9</sup>



| PuraPly®AM

## PROVEN REAL-WORLD EFFECTIVENESS

### THE STUDY

**N=307**  
**28 Sites**

Prospective, multicenter  
cohort study<sup>4</sup>

**Large**  
**Difficult-to-Heal**  
**Wounds**

12.9 cm<sup>2</sup> mean wound area<sup>4</sup>

### THE RESULTS

**86%** of wounds demonstrated improvement in wound bed conditions<sup>4</sup>



Increased  
granulation  
tissue



Reduced  
exudate



Readiness for  
other advanced  
skin substitutes

**85%** of wounds achieved >75% reduction in volume<sup>4</sup>

ECM=extracellular matrix; PHMB=polyhexamethylene biguanide


Note: PuraPly AM resists microbial colonization within the product and reduces microbes penetrating through it. PuraPly AM will naturally be resorbed into the wound and is not intended to be removed.<sup>1</sup>

# SCIENTIFIC EVIDENCE

## ANTIMICROBIAL EFFECTIVENESS WITHIN PURAPLY AM<sup>2,\*</sup>

>99%

MRSA reduction from post-debridement baseline



\*P<0.05 vs pre- and post-debridement baseline; <sup>b</sup>P<0.05 vs Aquacel Ag and PriMatrix Ag; <sup>c</sup>P<0.05 vs BlastX; <sup>d</sup>P<0.05 vs pre-debridement baseline


Data shown compared MRSA (methicillin-resistant *Staphylococcus aureus*) colonies in each wound, using a porcine deep reticular dermal wound model

<sup>1</sup>In a study evaluating the antimicrobial effectiveness within PuraPly AM and PuraPly XT versus a variety of other wound products

## PURAPLY AM LOW CYTOTOXICITY<sup>2,\*</sup>

>94%



Fibroblast viability at 48 hours



\*P<0.001 vs Blast X

Data shown measured cell proliferation and cell viability using human dermal fibroblasts in media conditioned with test materials

## PURAPLY<sup>®</sup> AM HELPS YOU MANAGE WOUNDS FROM HEAD-TO-TOE WITH A WIDE VARIETY OF SIZES<sup>1</sup>



\* Abrasions, lacerations, second-degree burns, skin tears

† Donor sites/grfts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence

**References:** **1.** PuraPly Antimicrobial [package insert]. Canton, MA: Organogenesis Inc; 2023. **2.** Davis SC, et al. *Int Wound J.* 2022;19(1):86-99. **3.** Brantley J, et al. *Wounds Int.* 2016;7(3):1-5. **4.** Bain MA, et al. *J Comp Eff Res.* 2020;9(10):691-703. **5.** Data on file. PDR-0008. Organogenesis Inc. **6.** Carpenter S, et al. *Wounds.* 2016;28(6 suppl):S1-S20. **7.** Data on file. PDR-0005. Organogenesis Inc. **8.** Gilbert P, et al. *J Appl Microbiol.* 2005;99(4):703-715. **9.** Hübner NO, et al. *Skin Pharmacol Physiol.* 2010;23(1 suppl):17-27.